Trials and Research Search | SIU School of Medicine

Showing: 11 Results

Trial

Neuroscience Institute

18-513: A Randomized Clinical Trial of Andexanet Alfa in Acute Intracranial Hemorrhage in Patients Receiving an Oral Factor XA Inhibitor

Active not recruiting

18-513: The purpose of this study is to evaluate the effect of andexanet alfa (andexanet) versus usual care on the rate of effective homostasis.

Trial

Neurology

A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Outpatient, Parallel-Group Study to Assess the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older with Stereotypical Prolonged Seizures

Active recruiting

The purpose of this study is to compare the success of a single admnistration of Staccato alprazolam compared with placebo in rapidly terminating a seizure episode within 90seconds after IMP administration.

Trial

Pediatrics

A Randomized, Double Blind, Parallel-group, Placebo Controlled Study to Evaluate the Efficacy and Safety of IBP-9414 in Premature Infants 500-1500g Birth Weight in the Prevention of Necrotizing Enterocolitis - The Connection Study

Active recruiting

The purpose of the clinical study is to compare the effectiveness of IBP-9414 treatment against placebo in preventing necrotizing enterocolitis in premature infants.

Treatments: Prevention of necrotizing enterocolitis in premature infants

Trial

Neurology

A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimer’s Disease (TargetTau-1)

Active not recruiting

The purpose of this study is to assess the effect of BMS-986446 vs placebo on delay of cognitive memory and functional decline in participants (age 50-80) with early Alzheimer's Disease.

Trial

Neurology

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Focal-Onset Seizures

Active recruiting

The primary objective of this study is to assess the effect of XEN1101 versus placebo on reducing focal seizure frequency.

Trial

Neurology

A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures

Active recruiting

The primary objective is to assess the effect of XEN1101 versus placebo on reducing PGTCS frequency in subjects with PGTCS.

Trial

Neurology

A Seamless Phase 2A-Phase 2B Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients with Early Alzheimer’s Disease (BenfoTeam)

Active recruiting

The purpose of this study is to learn more about the safety, effectiveness and tolerability of the study drug called Benfotiamine, to determine whether it delays or slows the progression of the symptoms of early Alzheimer’s disease.

Trial

Neurology

An Open-Label, Multicenter, Outpatient Extension Study to Evaluate the Safety and Tolerability of Staccato Alprazolam in Study Participants 12 Years of Age and Older with Stereotypical Prolonged Seizures

Active recruiting

The primary endpoint of this study is to evaluate the long-term safety and tolerability of Staccato alprazolam.

Trial

Neurology

Caregiver Characteristics That May Predict When Patients With Alzheimer Disease Are Placed in Long Term Care Facilities

Active recruiting

This research will be conducted by the SIU Memory and Aging Network (MAN), which comprises 38 sites that evaluate and treat patients with dementia throughout non-metropolitan Illinois. AD patients and their caregivers who are living in private homes will be recruited. Primary outcome measures will be the ratings of the caregiver’s physical status (grip strength, walking speed, and score on the Timed Up-and-Go Test11 and the rating of the caregiver’s chronic medical illness burden using the Cumulative Illness Rating Scale (Geriatric).12,13 The patient and caregiver dyad is required.

Trial

Neurology

Roche: A Phase IIB, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of intravenous prasinezumab in participants with early Parkinson's disease

Active not recruiting

This study will evaluate the efficacy, safety, and pharmacokinetics of prasinezumab compared with placebo in patients with early Parkinson's disease (PD).

Clinical trials and research studies